GeneQuine Biotherapeutics Secures more than €9 Million

28-Jan-2021

GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has raised €5.4 million in Series A financing and €3.65 million non-dilutive funding bringing the total amount raised to €9.05 million. The Series A ...

more

i3 Membrane receives 7 figure sum for development and market launch

26-Jan-2021

Four investors are financing the further growth of i3 Membrane GmbH. High-tech venture capital investor HTGF from Bonn, Germany, and three private investors are together investing a 7 figure sum in the further development and market launch of new separation technology for biological molecules. ...

more

LignoPure secures € 2.2 Million seed round

20-Jan-2021

LignoPure invented a unique approach to replace plastics through utilization of wood waste and the team just closed its seed round with HTGF, IFH and Tanovis AG to scale its own technology for the transformation of lignin – a byproduct of the pulp and paper industries and biorefineries – into ...

more

Start-up announces $24 million Series A financing and appoints Jason T. Gammack as CEO

18-Dec-2020

Resolve Biosciences, the pioneer in Molecular Cartography™, announced the completion of a $24 million Series A financing round and the appointment of Co-founder Jason T. Gammack as Chief Executive Officer. The company’s Molecular Cartography platform is a groundbreaking multi-analyte and highly ...

more

International pool invests ~ 2 Mio € in medicine start-up mediaire

17-Dec-2020

HTGF, primeCROWD and LIFTT are part of an international round for the development of “Deep learning diagnostic” which allows faster, more accurate and safer MRI analysis. Expansion into European markets will start in 2021 accompanied by a significant expansion of product portfolio mediaire, the ...

more

One of the largest trade sales of a VC-financed German biotech start-up in the last 20 years - first HTGF unicorn

11-Dec-2020

Gilead Sciences, Inc. and MYR GmbH announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 bn in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €0.3 bn million (both ...

more

Financing enables company to embark on additional targets and expand ADC technology reach

27-Nov-2020

Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of leading European investors comprising ...

more

lino Biotech closes seed financing round

19-Nov-2020

After almost a decade of initial invention and joint research on the Focal Molography technology at Roche, a leading player in the diagnostics and pharmaceutical area, and ETH Zurich as one of Europe’s most renowned research institutes, lino Biotech AG has licensed the technology to further ...

more

For the first time, Patient-Reported Outcome Measures are systematically linked to clinical data to improve treatment and research

23-Oct-2020

The digital health start-up heartbeat medical has closed a Series A financing round with a volume of 5 million euros. The funds will be used to support organisational development and the expansion of capabilities of skills in the field of data analysis. There is a great need for better data in ...

more

EIB backs Atriva Therapeutics

22-Oct-2020

The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of a novel therapy treating ...

more